

CAPRELSA (VANDETANIB) PA SUMMARY

STATUS: Non-Preferred

LENGTH OF AUTHORIZATION: 3 months

PA CRITERIA:

- ❖ Approvable for the diagnosis of symptomatic or progressive medullary thyroid cancer that is unresectable locally advanced or metastatic
- ❖ Prescriber and pharmacy must be enrolled in the Caprelsa REMS program.
- ❖ Prescriber must monitor ECGs, serum potassium, calcium, magnesium, and TSH at least every 3 months.

EXCEPTIONS:

- ❖ Exceptions to these conditions of coverage are considered through the prior authorization process.
- ❖ The Prior Authorization process may be initiated by calling **SXC Health Solutions at 1-866-525-5827**.

PA and APPEAL PROCESS:

- ❖ For online access to the PA process please go to www.mmis.georgia.gov/portal, highlight the pharmacy link on the top right side of the page, and click on “prior approval process”.

QUANTITY LEVEL LIMITATIONS:

- ❖ For online access to the current Quantity Level Limit please go to www.mmis.georgia.gov/portal, highlight Provider Information and click on Provider Manuals. Scroll to the page with Pharmacy Services Part II and select that manual.